Teradyne Gears Up to Report Q2 Earnings: What's in the Offing?

24.07.25 19:57 Uhr

Werte in diesem Artikel
Aktien

78,00 EUR 1,50 EUR 1,96%

79,07 EUR 0,35 EUR 0,44%

Indizes

6.370,9 PKT -18,9 PKT -0,30%

Teradyne TER is scheduled to report its second-quarter 2025 earnings results on July 29.For the second quarter of 2025, TER expects revenues between $610 million and $680 million. The company anticipates non-GAAP earnings between 41 cents and 64 cents per share. The Zacks Consensus Estimate for revenues is pegged at $646.1 million, indicating a decrease of 11.5% from the year-ago quarter’s reported value.The consensus mark for second-quarter earnings is pegged at 54 cents per share, unchanged over the past 30 days. This projection indicates a significant year-over-year decrease of 37.21% from the prior-year figure.Teradyne, Inc. Price and EPS Surprise Teradyne, Inc. price-eps-surprise | Teradyne, Inc. QuoteTeradyne earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average positive surprise being 14.26%.Let’s see how things have shaped up for the upcoming announcement:Factors to Note Ahead of TER’s Q2 ResultsTER’s second-quarter 2025 performance is likely to have been affected by continued macroeconomic uncertainty, including tariff risks, evolving trade policies and fluctuations in end-customer demand. This headwind is anticipated to have hurt the company in the quarter under review.Teradyne expects a decline in Memory test system revenues in the second quarter of 2025, as customers continue to utilize previously installed high-bandwidth memory test capacity rather than investing in new systems.In Mobile, TER anticipates lower revenues in the second quarter of 2025. While the company has not observed major pushouts in this segment, uncertainty remains around the potential impact on end-market demand.Teradyne expects a small increase in cost of sales and operating expenses in the second quarter of 2025, while gross margin is now expected to decrease sequentially, driven by product mix and lower volume.What Our Model SaysAccording to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.Teradyne currently has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.Stocks to ConsiderHere are some companies worth considering, as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases:Enovix Corporation ENVX currently has an Earnings ESP of +10.45% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.Enovix shares have appreciated 33.9% year to date. Enovix is scheduled to release its second-quarter 2025 results on July 31. Lumentum LITE currently has an Earnings ESP of +8.73% and a Zacks Rank #1.Lumentum shares have appreciated 22.6% year to date. Lumentum is set to report its fourth-quarter fiscal 2025 results on Aug. 12. Bumble BMBL has an Earnings ESP of +11.15% and a Zacks Rank #1.Bumble shares have appreciated 4% year to date. Bumble is set to report its second-quarter 2025 results on Aug. 6. 7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teradyne, Inc. (TER): Free Stock Analysis Report Lumentum Holdings Inc. (LITE): Free Stock Analysis Report Bumble Inc. (BMBL): Free Stock Analysis Report Enovix Corporation (ENVX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Q2 und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Q2

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Q2

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Teradyne Inc.

Wer­bung

Analysen zu Teradyne Inc.

DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
DatumRatingAnalyst
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
24.01.2018Teradyne BuyStifel, Nicolaus & Co., Inc.
05.07.2017Teradyne BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
21.11.2017Teradyne HoldDeutsche Bank AG
29.10.2015Teradyne Sector WeightPacific Crest Securities Inc.
11.06.2012Teradyne neutralUBS AG
DatumRatingAnalyst
30.07.2009Teradyne ErsteinschätzungMorgan Stanley
22.12.2008Teradyne underweightJP Morgan Chase & Co.
06.12.2005Update Teradyne Inc.: UnderperformGoldman Sachs
06.12.2005Teradyne underperformGoldman Sachs

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teradyne Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen